Why are there deadly drugs?
Author:
Open Access
- 5 February 2015
- journal article
- editorial
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 27
Abstract
Some drugs eventually have to be removed from the market because of a negative benefit-to-harm ratio, including an excess of mortality. Drug safety is the result of multiple factors, commencing with how clinical trials are designed, the information generated by and/or hidden through these trials, trial analysis by drug regulatory authorities (DRAs) and the amount of information that DRAs choose to release, the amount of published information regarding drug safety, the effectiveness of postmarket surveillance systems in recognizing and reporting adverse drug reactions, and the structure of DRAs such as the United States Food and Drug Administration and its equivalent in other countries. This commentary will look at each of these issues in order to highlight the problems in the current approach to drug safety and finally indicate how some of these deficiencies should be addressed. Please see related article: http://dx.doi.org/10.1186/s12916-014-0262-7Keywords
This publication has 16 references indexed in Scilit:
- New Drugs and SafetyArchives of internal medicine (1960), 2012
- Response to John Ferejohn's review of Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDAPerspectives on Politics, 2012
- Reporting of Harm in Randomized Controlled Trials Published in the Urological LiteratureJournal of Urology, 2010
- Bringing the FDA's Information to MarketArchives of internal medicine (1960), 2009
- Reporting of Safety Results in Published Reports of Randomized Controlled TrialsArchives of internal medicine (1960), 2009
- Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive ImpairmentJAMA, 2008
- Drug-Review Deadlines and Safety ProblemsNew England Journal of Medicine, 2008
- Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005Archives of internal medicine (1960), 2007
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- Evaluation of the Extent of Under-Reporting of Serious Adverse Drug ReactionsDrug Safety, 2004